BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26694174)

  • 1. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53.
    Yang MC; Lin RW; Huang SB; Huang SY; Chen WJ; Wang S; Hong YR; Wang C
    Cell Cycle; 2016; 15(3):394-402. PubMed ID: 26694174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
    Wang C; Huang SB; Yang MC; Lin YT; Chu IH; Shen YN; Chiu YH; Hung SH; Kang L; Hong YR; Chen CH
    PLoS One; 2015; 10(3):e0120913. PubMed ID: 25811469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage.
    Lin RW; Ho CJ; Chen HW; Pao YH; Chen LE; Yang MC; Huang SB; Wang S; Chen CH; Wang C
    Cell Cycle; 2018; 17(17):2175-2186. PubMed ID: 30198376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bax/Bak activation in the absence of Bid, Bim, Puma, and p53.
    Zhang J; Huang K; O'Neill KL; Pang X; Luo X
    Cell Death Dis; 2016 Jun; 7(6):e2266. PubMed ID: 27310874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo.
    Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S
    PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
    Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate.
    Hastak K; Agarwal MK; Mukhtar H; Agarwal ML
    FASEB J; 2005 May; 19(7):789-91. PubMed ID: 15764647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells.
    Li X; Li B; Ni Z; Zhou P; Wang B; He J; Xiong H; Yang F; Wu Y; Lyu X; Zhang Y; Zeng Y; Lian J; He F
    Mol Cancer Ther; 2017 Sep; 16(9):1806-1818. PubMed ID: 28533436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
    Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
    Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis.
    Follis AV; Chipuk JE; Fisher JC; Yun MK; Grace CR; Nourse A; Baran K; Ou L; Min L; White SW; Green DR; Kriwacki RW
    Nat Chem Biol; 2013 Mar; 9(3):163-8. PubMed ID: 23340338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of p53 contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin.
    Lim DY; Park JH
    Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1060-8. PubMed ID: 19264955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family.
    Ohno I; Eibl G; Odinokova I; Edderkaoui M; Damoiseaux RD; Yazbec M; Abrol R; Goddard WA; Yokosuka O; Pandol SJ; Gukovskaya AS
    Am J Physiol Gastrointest Liver Physiol; 2010 Jan; 298(1):G63-73. PubMed ID: 19762431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
    Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
    Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A; Villedieu M; P├ętigny-Lechartier C; Brotin E; Louis MH; Abeilard E; Giffard F; Guercio M; Briand M; Gauduchon P; Lheureux S; Poulain L
    Cancer Lett; 2014 Jun; 348(1-2):38-49. PubMed ID: 24650799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.